Blogs | MedChemExpress

MC0704 is a STAT3 Inhibitor for Triple-negative Breast Cancer Research

MC0704 is a STAT3 inhibitor (IC50=2.13 μM), which can be used for the research of metastatic triple-negative breast cancer (mTNBC).
MS8815 is a EZH2 PROTAC Degrader for Targeting Triple-Negative Breast Cancer (TNBC)

MS8815 is a selective EZH2 PROTAC degrader. MS8815 can be used for the research of triple-negative breast cancer (TNBC),
Tigatuzumab (CS-1008) is a Humanized Death Receptor 5 (DR5) IgG1 mAb

Tigatuzumab, a humanized IgG1 anti-DR5 monoclonal antibody, is aTRAIL-R2 agonist, with potent anticancer effects.
CYD-4-61 is a Bax Activator Used for Breast Cancer Research

CYD-4-61 is a novel Bax activator. It induces cytochrome c release, mitochondrial membrane penetration, consequently leads to cell apoptosis.
STX-0119 is a Selective, Orally Active STAT3 Dimerization Inhibitor

STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 shows potent antitumor activity.
β-Amanitin is a cyclic peptide toxin, inhibits eukaryotic RNA polymerase II and III and protein synthesis.

β-Amanitin is a cyclic peptide toxin, inhibits eukaryotic RNA polymerase II and III. It inhibits DNA transcription, and protein synthesis.
Capivasertib (AZD5363) is an Orally Active pan-AKT Kinase Inhibitor

Capivasertib is an orally active AKT inhibitor with pharmacodynamic activity in multiple solid and hematologic tumors.
DGY-06-116 is an Irreversible Covalent and Selective Src Inhibitor

DGY-06-116 is an irreversible covalent, selective Src inhibitor with an IC50 of 3nM. DGY-06-116 inhibits FGFR1 with an IC50 of 8340 nM.
LJI308 is a Pan-Ribosomal S6 Kinase (RSK) Inhibitor

LJI308 inhibits the phosphorylation of RSK and YB-1 after irradiation, treatment with EGF, and in cells expressing a KRAS mutation.
Trilaciclib is an Orally Active CDK4 and CDK6 Inhibitor

Trilaciclib is a CDK4/6 inhibitor with IC50s of 1 nM/4 nM for CDK4/6, respectively. Use for chemotherapy-induced myelosuppression in vivo.

Name
Email *

	Sorry, but the email address you supplied was invalid.

Blogs (25)